Disease relevance of SPACA3

• CONCLUSIONS: SLLP1 is a novel cancer-testis antigen in hematologic malignancies and is capable of eliciting B-cell immune responses in vivo in cancer-bearing individuals [1].
• The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies [1].
• RESULTS: SLLP1 was aberrantly expressed in the tumor cells from 2 of 9 acute myeloid leukemia, 3 of 11 chronic lymphocytic leukemia, 4 of 14 chronic myeloid leukemia, and 6 of 17 multiple myeloma [1].
• SLLP1 mRNA (size, approximately 1 kb) appeared to be expressed only in the testis and in the Burkitt lymphoma Raji cell line [2].
• We reviewed 29 lymphomas and classified them as SLL (13 cases), MCL (8 cases), and SLLP (8 cases) based on histology and expression of cytoplasmic immunoglobulin light chain [3].

High impact information on SPACA3

• In this study, we determined whether SLLP1 is a novel cancer-testis antigen in hematologic malignancies EXPERIMENTAL DESIGN: SLLP1 expression in hematologic tumor cells and normal tissues was determined using a combination of reverse transcription-PCR, real-time PCR, and Western blot analysis [1].
• The gene SPACA3 encodes SLLP1 and contains five exons at locus 17q11 [2].
• We report the presence of a unique, non-bacteriolytic, c (chicken or conventional type) lysozyme-like protein, SLLP1, in the acrosome of human sperm [2].
• Small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), and SLL plasmacytoid (SLLP) are malignant neoplasms of small B cells that may have overlapping cytologic features [3].

Anatomical context of SPACA3

• SLLP1 exhibited a very restricted normal tissue expression, being found only in testis/spermatozoa [1].
• The processed form of SLLP1, which showed an exon-intron organization similar to human c lysozyme, was the major isoform in the acrosome of ejaculated sperm [2].

Analytical, diagnostic and therapeutic context of SPACA3

• The presence of antibodies against SLLP1 was determined by ELISA analysis [1].
• Our results, therefore, support SLLP1 as a protein target appropriate for additional in vitro study to define its suitability for immunotherapy [1].
• By immunohistochemistry, we found that the expression of CD23 in SLL discriminates between SLL and MCL and that the expression of CD23 and CD43 in SLL discriminates between SLL and SLLP [3].

References